Search clinical trials for: 2nd Line Therapy

Total 59064 results

Peking University First Hospital

Recruiting

Fruquintinib Plus Everolimus as 2nd Line Therapy of ccRCC Patients Progressed Post IO and TKI Therapy

Renal Cell Carcinoma, Clear Cell, Somatic

China
Iovance Biotherapeutics, Inc.

Recruiting

A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer

Metastatic Melanoma | Unresectable Melanoma | Stage IV Non-small Cell Lung Cancer | Stage III Non-small Cell Lung Cancer

United States
University of Milano Bicocca

Recruiting

Retrospective Study of 2nd-line Therapies After CDK4/6i + Hormonal Therapy in HR+/HER2- Advanced Breast Cancer (HERMIONE-13)

Advanced Breast Cancer | Hormone Receptor Positive Breast Carcinoma | HER2-negative Breast Cancer

Italy
University of Alabama at Birmingham
National Institute of Allergy and Infectious Diseases (NIAID); Indiana University and other collaborators

Recruiting

Kuwa Free! - Live Free!

HIV Infections | Contraception | Drug-drug Interaction

Kenya
Qian Wenbin

Not yet recruiting

Sintilimab Plus R-GemOx as Second-line Salvage Therapy in Patients With R/R DLBCL

Diffuse Large B Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Relapsed Diffuse Large B-Cell Lymphoma

China
Iovance Biotherapeutics, Inc.

Recruiting

Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer

Metastatic Non Small Cell Lung Cancer

United States, Canada, Germany, Netherlands, Switzerland
Yonsei University

Recruiting

Regorafenib, C-kit Mutated Malignant Melanoma, 2nd Line Therapy

Melanoma

Korea, Republic of
Institut Cancerologie de l'Ouest

Active, not recruiting

Prediction of Response to 2nd-line Hormone Therapy by FES CT/PET in Patients With Metastatic Breast Cancer (TEP-FES)

Metastatic Breast Cancer

France
Emory University
National Cancer Institute (NCI); Sirtex Medical

Withdrawn

Radioembolization of Metastatic Breast Cancer to the Liver as a 2nd/3rd Line Therapy

Anatomic Stage IV Breast Cancer AJCC v8 | Prognostic Stage IV Breast Cancer AJCC v8 | Metastatic Breast Carcinoma | Metastatic Carcinoma in the Liver

United States
Boehringer Ingelheim

Active, not recruiting

VARGADO - Vargatef in 2nd-line Therapy of Non-Small Cell Lung Cancer (NSCLC)

Carcinoma, Non-Small-Cell Lung

Germany
The Lymphoma Academic Research Organisation

Active, not recruiting

Axi-Cel as a 2nd Line Therapy in Patients With Relapsed/Refractory Aggressive B Lymphoma Ineligible to Autologous Stem Cell Transplantation

B-cell Lymphoma Recurrent | B-Cell Lymphoma Refractory

France, Belgium
Merck Sharp & Dohme LLC

Terminated

Efficacy and Safety Study of Pembrolizumab (MK-3475) Versus Paclitaxel in Asian Participants With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Who Progressed After First-line Therapy With Platinum and Fluoropyrimidine (MK-3475-063/KEYNOTE-063)

Gastric Neoplasms | Gastroesophageal Junction Adenocarcinoma

China, Korea, Republic of, Malaysia, Taiwan
AIO-Studien-gGmbH
Servier Deutschland GmbH; Crolll Gmbh

Active, not recruiting

2nd-line Therapy With Nal-IRI After Gem/Nab-pac in Advanced Pancreatic Cancer - Predictive Role of 1st-line Therapy (PREDICT)

Metastatic Pancreatic Cancer | Locally Advanced Pancreatic Cancer

Germany
AIO-Studien-gGmbH
Bristol-Myers Squibb

Completed

A Multicenter Open-label Phase II Trial to Evaluate Nivolumab and Ipilimumab for 2nd Line Therapy in Elderly Patients With Advanced Esophageal Squamous Cell Cancer (RAMONA)

Esophageal Cancer | Gastrooesophageal Cancer | Oesophageal Cancer | GastroEsophageal Cancer | Esophageal Cancers NOS | Oesophageal Cancer Metastatic | Esophageal Cancer Metastatic | Oesophageal Cancer Nos

Germany
AstraZeneca

Completed

A Single Arm, Tolerability and Safety Phase IV Study of Fulvestrant(Faslodex® ) as 2nd Line and Later Therapy in Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer

Metastatic Breast Cancer | Locally Advanced or

Korea, Republic of
Seoul St. Mary's Hospital
Boehringer Ingelheim

Active, not recruiting

Retrospective Multi-cohort Study of Frontline Afatinib Followed by 2nd Line Therapy Including Osimertinib, Chemotherapy or Other Therapy

NSCLC

Korea, Republic of
Ipsen

Withdrawn

Study on the Utilization of Cabozantinib in Adult Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC) in 2nd Line Treatment Following Prior Vascular Endothelial Growth Factor (VEGF)-Targeted Therapy Under Real-real Life Clinical Setting in France. (CAROLINE)

Renal Cell Carcinoma
Abramson Cancer Center of the University of Pennsylvania

Completed

Etirinotecan Pegol (NKTR-102) in NSCLC

Metastatic Non Small Cell Lung Cancer | Recurrent Non Small Cell Lung Cancer

United States
Hutchison Medipharma Limited
Sun Yat-sen University; Fudan University

Completed

A Phase Ib Study of Fruquintinib in 3rd Line mCRC

Colorectal Cancer

China
Instituto do Cancer do Estado de São Paulo
Pfizer

Unknown

Biomarker Study of Pts With Metastatic ccRCC Undergoing Sequential Therapy With 1st Line Sunitinib and 2nd Line Axitinib (SuAx)

Clear Cell Renal Cell Carcinoma

Brazil
Amgen

Completed

SPIRITT - Second-Line Panitumumab Irinotecan Treatment Trial

Cancer | Metastatic Colorectal Cancer | Colorectal Cancer | Rectal Cancer | Metastatic Cancer | Colon Cancer
Asan Medical Center
Boryung Pharmaceutical Co., Ltd

Completed

Etoposide, Methylprednisolone, High-dose Cytarabine and Oxaliplatin as 2nd Line Therapy for Non-Hodgkin's Lymphoma (NHL)

Non-Hodgkin's Lymphoma

Korea, Republic of
Genesis Pharma S.A.

Completed

A Retrospective Chart Review Study of the Outcomes of 2nd Line Therapy With LEn/Dex in Greek Patients With R/R Multiple MyEloma and the Treatment PatterNs Following Progressive Disease (LEGEND)

Relapsed/Refractory Multiple Myeloma

Greece
Oshadi Drug Administration

Unknown

Oshadi D and Oshadi R in Combination With Docetaxel, as 2nd Line Therapy for Metastatic Non Small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung

Israel
Zhejiang Cancer Hospital

Unknown

Capecitabine or Endocrinotherapy as a Maintenance Therapy Regimen at Least 2nd Line in Hormone Receptor Positive and HER2 Negative Metastatic Breast Cancer

Breast Cancer

China
Shandong Cancer Hospital and Institute
AstraZeneca

Unknown

Open Label, Prospective Study to Investigate Efficacy and Safety of AZD9291 in BM From NSCLC Patients With EGFR T790M

Nonsmall Cell Lung Cancer | Brain Metastases | EGFR-TKI Resistant Mutation | AZD9291
Hellenic Oncology Research Group
University Hospital of Crete

Completed

Weekly Paclitaxel/Carboplatin/Bevacizumab as First Line Therapy for Triple Negative Breast Cancer

Breast Cancer

Greece
Cantonal Hospital of St. Gallen
Celgene Corporation; Amgen; Mundipharma Medical Company; Mundipharma Research GmbH...

Completed

Bendamustine, Lenalidomide (Revlimid®) and Dexamethasone (BRd) as 2nd-line Therapy for Patients With Relapsed or Refractory Multiple Myeloma (BRd)

Multiple Myeloma

Switzerland
Eli Lilly and Company

Completed

A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib (REACH)

Hepatocellular Carcinoma

United States, Canada, Belgium, Germany, Israel, Korea, Republic of, Spain, Australia, Austria, Brazil, France, Italy, Japan, Portugal, Taiwan, Romania, Bulgaria, Czech Republic, Finland, Hong Kong, Hungary, Netherlands, Norway, Phili... and more
University of Roma La Sapienza

Unknown

Empirical vs 2nd Line Antibiotic Therapy in Health-care Associated Infections in Cirrhosis

Cirrhosis

Italy
Accelerated Community Oncology Research Network
Amgen

Completed

1st or 2nd Line MBC (Metastatic Breast Cancer) With Previous Avastin (Bevacizumab) Therapy

Breast Cancer

United States
EMD Serono

Completed

Safety of Adding IMO-2055 to Erlotinib + Bevacizumab in 2nd Line Treatment for Patients With NSCLC

Non-Small Cell Lung Cancer

United States
Spanish Cooperative Group for the Treatment of...
Amgen

Completed

Panitumumab in Combination With Irinotecan Chemotherapy as 2nd-line Therapy in Subjects With mCRC

Metastatic Colorectal Cancer

Spain
AstraZeneca

Completed

Comparing Efficacy Between Anti-microtubule and Non-anti-microtubule as 3th Therapy After 2nd Line EGFR-TKI Therapy

Cancer

Taiwan
Janssen Pharmaceutical K.K.

Completed

Phase II Clinical Study of Pegylated Liposomal Doxorubicin Hydrochloride Injection as 2nd-line or Later Therapy in Patients With Mullerian Carcinoma (Epithelial Ovarian Carcinoma, Primary Carcinoma of Fallopian Tube, Peritoneal Carcinoma) Having Prior Platinum-Based Chemotherapy

Ovarian Neoplasms
Taiho Oncology, Inc.
Quintiles, Inc.

Completed

Phase 2 Study of S-1 as 2nd Line Therapy in Metastatic Pancreatic Cancer

Secondary Malignant Neoplasm of Pancreas
Taiho Oncology, Inc.
Quintiles, Inc.; United BioSource, LLC

Completed

Phase 2 Study of S-1 as 2nd Line Therapy in Advanced Non-Small Cell Lung Cancer

Advanced Non-Small Cell Lung Cancer
Sun Yat-sen University

Unknown

Study of Enahnced External Counterpulsation to Treat Coronary Heart Disease (PROBE-EECP)

Coronary Artery Disease

China
Hellenic Oncology Research Group

Completed

Docetaxel/Epirubicin/Bevacizumab as First Line Therapy for Metastatic HER2 Negative Breast Cancer

Breast Cancer

Greece
AGO Study Group
Essex Pharma GmbH; MedServ. GmbH, Wiesbaden

Completed

Combination Chemotherapy Consisting of Pegylated Liposomal Doxorubicin and Carboplatin in Malignant Gynecologic Tumours

Cervical Cancers | Cancer of the Ovary Treated as 2nd Line Therapy | Muellerian Mixed Tumours | Tumours of the Uterus | Non-Epithelial Ovarian Tumours

Germany
Hellenic Oncology Research Group
University Hospital of Crete

Completed

Erlotinib as 1st Line Treatment in NSCLC Stage IIIB/IV

Non Small Cell Lung Cancer

Greece
Bristol-Myers Squibb

Recruiting

Observational Study in Japanese Patients With Peripheral T-Cell Lymphoma Who Received Second-Line Therapy

Peripheral T-cell Lymphoma

Japan
N.N. Petrov National Medical Research Center of...

Recruiting

High-dose Chemotherapy as Second-line Drug Therapy for Relapsed Germ Cell Tumors (GERMAN)

Germ Cell Tumor

Russian Federation
Cancer Institute and Hospital, Chinese Academy...

Not yet recruiting

Fruquintinib and Albumin-paclitaxel Combined With or Without PD-1 Antibody in 2nd-line Treatment of G/GEJ Adenocarcinoma

Gastric Cancer
Sunshine Guojian Pharmaceutical (Shanghai) Co.,...

Not yet recruiting

A Phase II Study of SSGJ-707 Combination Therapy in Advanced NSCLC Patients

First-line Advanced NSCLC Patients

China
Riphah International University

Recruiting

Effect of Superficial Back Line Relaxation Technique on Hamstring Flexibility in Non Specific Low Back Pain Patients

Low Back Pain, Mechanical | Hamstring Flexibility

Pakistan
Celgene
Bristol-Myers Squibb

Recruiting

A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation (KarMMa-9)

Multiple Myeloma

Austria, United States, Spain, Australia, Japan, France, Israel, Italy, Canada, Greece, Belgium, Norway, Romania, Czechia, Denmark, Germany, Korea, Republic of, United Kingdom, Poland
Danish Research Centre for Magnetic Resonance
Department of Physical- and Occupational Therapy; Hvidovre Hospital; Department... and other collaborators

Not yet recruiting

Neuroimaging of Babies During Natural Sleep to Assess Typical Development and Cerebral Palsy (NIBS-CP)

Cerebral Palsy | Development, Infant | Infant Development

Denmark
Bristol-Myers Squibb

Not yet recruiting

A Study to Assess the Effectiveness and Safety of Ozanimod in Chinese Adults With Relapsing Multiple Sclerosis

Relapsing Multiple Sclerosis

China
Ioannis A. Malogiannis
National and Kapodistrian University of Athens; Attikon Hospital; University... and other collaborators

Recruiting

Specialized Healthcare Service for BPD Patients: Athens Trial (BPDAS)

Other Mental Conditions

Greece

Search clinical trials for: 2nd Line Therapy

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Belarus

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations